• www.hausbio.com
• @_metaderm_
• www.facebook.com/metaderm

A Little About Me

Our Team is a Bunch of Science and Pharma Geeks - ›

Michael Centola, Ph.D. Immunology & Biochemistry Dr. Centola is the co-founder, CEO, and CSO at Haus Bioceuticals Inc. He also founded Crescendo Bioscience Inc, a pioneering molecular diagnostics company, where he served as president, CSO, and board member. At Crescendo he directed seed-to-venture funding, business development, product pipeline, and IP strategy. He has also served CSO, scientific advisor, and board member at multiple biotech and pharmaceutical companies. Dr. Centola has extensive R&D experience in therapy, device, and cosmecutical development. This includes: the 1st positional cloning of a rheumatic disease gene and translation of the results into the 1st molecular genetic test for inflammatory arthritis diagnosis, initiating and directing R&D and commercialization of the 1st molecular diagnostic test in rheumatology (which has grown to be among the most successful commercial products in this space), and initiating global cosmeceutical development for Wella Inc.  He is an author on over 90 peer-reviewed publications and holds multiple patents in these areas. He also has extensive clinical trial experience including: Certification in 1998 by the National Institutes of Health's Clinical Research Training Program, and directing over 2 dozen clinical trials. He has been instrumental in enabling Haus' core competency; bringing an evidenced-based approach to the development of natural medicines.

›Adam Payne, MBA - Mr. Payne is Chairman and President of Haus.  He shares executive responsibility with Dr. Centola and Dr. Alex.  Mr. Payne has been a serial bio-entrepreneur with two decades of senior experience.  In the last 7 years He has co-founded four life-science based companies and raised more than $35 Million in venture backed and angel investment.  In the capacity as CEO he has lead the advancement of multiple therapeutic candidates from bench to IND application, to clinical trial, directing, designing and coordinating the regulatory, scientific and clinical aspects of these pursuits.  He has designed, overseen and implemented numerous animal and human clinical studies, coordinating with multiple PIs and Institutions.  He had early managerial experience from working in Russia from 1992 to 2003 where among a number of assignments; he was a manager of client services for a leading international advertising agency, head of PR/GR for a leading financial institution and also co-founded the currently leading management consulting company in Russia today.

Philip Alex, MD, PhD
Dr. Alex holds M.D. and Ph.D. degrees with experience in medicine and basic and clinical immunology from the Johns Hopkins Medical Institute and the University of Oklahoma Health Sciences. Dr. Alex is the Chief Medical Officer of Haus Bioceuticals, Inc and Executive Director of the Haus Clinical Trial Program, where he was instrumental in its development and the successful completion of several clinical trials for various therapeutic indications. Previously he has worked as Director of Clinical Research and International Clinical Trials for Riley Genomics, Inc. Dr. Alex is an expert in developing novel therapeutic modalities for inflammatory diseases from human trials and in-vivo models. He is also highly experienced in defining the mechanistic basis of therapeutic action, in-vitro intracellular signaling mechanisms, and multiplex cytokine studies in various in-vivo models of inflammation. He established the in vivo psoriasis model studies and directed the MetaDerm clinical trials. Dr. Alex was among the first to publish on the use of multiplex cytokine profiles and its utility for characterization of immunoregulatory mechanisms in autoimmune diseases and was on the first patent application for the use of a multiplex immunoassay for clinical diagnostics and therapeutic response. His work has resulted in the development of innovative immunological tools for disease activity assessments and to predict therapeutic outcome in several chronic inflammatory autoimmune diseases, effectively translating them into commercial products with high clinical utility. This tool (Vectra DA) is now available for clinical diagnostics. Dr. Alex has over 25 publications, 8 patents issued/applications, has served on editorial boards and scientific advisory panels, has been a reviewer for several high-impact journals, and has partnered with several academic and industry groups in the field.